Opinion|Videos|July 15, 2026

Treatment-Free Remission Implementation and Patient Counseling

How CML doctors plan treatment-free remission from day one, aiming for MR4.5, boosting adherence, and timing TKI stopping to reduce relapse.

Dr. Zeidner addresses treatment-free remission as the predominant contemporary CML discussion, exploring early patient counseling timing and implementation strategies. Both physicians emphasize introducing treatment-free remission concepts during initial consultations to establish realistic expectations, influence treatment selection, and enhance adherence understanding.

Dr. Cortes discusses multiple benefits of early treatment-free remission education: patient awareness of possibility despite acknowledging not all patients achieve eligibility, treatment option influence based on long-term goals, and adherence improvement through understanding deep molecular response importance for eventual discontinuation eligibility. Early counseling helps patients comprehend adherence significance and communicate medication compliance challenges or interruptions.

Treatment-free remission implementation follows established guidelines with modifications based on clinical experience. Dr. Cortes requires MR4.5 rather than MR4.0 responses and suggests 5-year treatment duration before discontinuation attempts, though accommodating patient preferences for earlier trials when meeting minimum 2-year sustained response requirements. Extended treatment duration potentially reduces relapse risks based on available outcome data.

Dr. Zeidner follows similar practices, preferring MR4.5 responses with 5-year treatment goals and minimum 2-year sustained deep molecular response duration. Earlier discontinuation occurs primarily for specific indications including pregnancy planning or patient-driven decisions after comprehensive counseling about timing implications.

Both physicians emphasize individualized approaches incorporating patient preferences, clinical context, and response patterns rather than rigid guideline adherence. Treatment-free remission discussions continue throughout treatment courses, adapting to evolving response patterns and patient circumstances while maintaining focus on achieving optimal outcomes through sustained deep molecular responses.


Latest CME